Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 251 to 260 of 281 total matches.
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
has not
been established.
DRUG INTERACTIONS — Use of live vaccines should
be avoided in patients being treated ...
The FDA has approved the subcutaneously
injected interleukin (IL)-4 receptor alpha antagonist
dupilumab (Dupixent – Sanofi/Regeneron)
for treatment of eosinophilic esophagitis (EoE)
in patients ≥12 years old who weigh ≥40 kg and
treatment of prurigo nodularis in adults. Dupilumab
is the first drug to be approved in the US for each
of these indications. It is also FDA-approved for
treatment of atopic dermatitis, asthma, and chronic
rhinosinusitis with nasal polyposis.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):18-20 doi:10.58347/tml.2023.1669b | Show Introduction Hide Introduction
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
or cannabinoids.30,31
DRUG INTERACTIONS — Cannabis and cannabinoids
cause drowsiness; additive adverse effects ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
of
these patients will develop SPMS.
Parenteral Drugs – Interferon beta (Avonex, Plegridy,
and others ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
endocrine neoplasia syndrome type 2.
DRUG INTERACTIONS — Semaglutide delays gastric
emptying and can alter ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.
Fenfluramine (Fintepla) for Dravet Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
.
DRUG INTERACTIONS — Coadministration with
stiripentol and clobazam increases plasma concentrations ...
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication. Stiripentol
(Diacomit) and cannabidiol (Epidiolex), a purified
product derived from marijuana, were approved earlier.
Semaglutide (Wegovy) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021 (Issue 1628)
syndrome type 2.
DRUG INTERACTIONS — By slowing gastric emptying,
semaglutide can delay the absorption ...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and established
cardiovascular disease, has now been approved in
a higher dose as Wegovy (Novo Nordisk) for chronic
weight management in adults with or without type 2
diabetes who have a body mass index (BMI) ≥30 kg/m2
or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity
(e.g., hypertension, dyslipidemia). An oral formulation
of semaglutide...
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
QT syndrome.
DRUG INTERACTIONS — Use of amisulpride with
dopamine agonists such as levodopa can ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Lemborexant (Dayvigo) for Insomnia
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020 (Issue 1601)
lemborexant
should be monitored for excessive sedation.
DRUG INTERACTIONS — Lemborexant is primarily ...
The FDA has approved lemborexant (Dayvigo – Eisai),
an orexin receptor antagonist, for treatment of sleep-onset
and/or sleep-maintenance insomnia in adults. It
is the second orexin receptor antagonist to be approved
for this indication; suvorexant (Belsomra) was the first.
Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
abnormalities should be corrected before taking the
drug. Sutab should be used with caution in patients ...
The FDA has approved an oral tablet formulation of
sodium sulfate, magnesium sulfate, and potassium
chloride (Sutab – Braintree) for colon cleansing prior
to colonoscopy in adults. A sodium sulfate-based oral
solution (Suprep) has been available in the US since
2010. Sutab is the second tablet formulation to be
approved for bowel cleansing prior to colonoscopy;
a sodium phosphate-based tablet (OsmoPrep) was
approved earlier.
Suflave — A Low-Volume Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
. www.fdbhealth.com/policies/drug-pricing-policy.
4. Also contains 22.72 g sodium sulfate, 6.72 g sodium bicarbonate ...
The FDA has approved Suflave (Sebela/Braintree), a
low-volume polyethylene glycol (PEG)- and sulfate-based
product for cleansing of the colon prior to
colonoscopy in adults. Other oral colonoscopy
preparations available in the US are listed in
Table 2. Suflave is marketed as tasting better than
other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51 doi:10.58347/tml.2023.1685b | Show Introduction Hide Introduction